Back to results
US 2026/0176239 A1Published application
Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
AssigneeBausch + Lomb Ireland Limited
InventorsMichael MUTZ, Fang WANG, Mei XIA
Life of this patent
Estimating the term…
Abstract
The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
Claims21
1-31. (canceled)
A pharmaceutical formulation, comprising:
- a mixture of crystal forms of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) having structure
- and
- a pharmaceutically acceptable excipient.
An aqueous formulation, comprising:
- a mixture of crystal forms of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) having structure
- wherein compound I is present as a suspension in the formulation in an amount ranging from about 0.5% w/v to about 3.5% w/v;
- a non-ionic surfactant;
- a suspending agent;
- a tonicity agent;
- a buffer;
- a salt;
- and
- optionally, a preservative.
6 more elements
Dependencies are inferred from the claim text.